Navigation Links
CombinatoRx to Present Combination High Throughput Screening (cHTS),Data at Upcoming AACR Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 12, 2007 - CombinatoRx, Incorporated (NASDAQ: CRXX), today announced that posters related to its oncology research efforts will be presented at the 98th Annual Meeting of the American Association for Cancer Research, April 14-18, 2007 in Los Angeles, CA.

"Systematic Screening of Targeted Chemical Combinations for Cancer Therapy", Heilbut, et.al. (Abstract #1410) will be presented on Sunday, April 15, 1-5pm PT and "Synergistic Enhancers of TRAIL-Mediated Apoptosis: A Quantitative Parallel Comparison of TRAIL-Small Molecule Synergies using cHTS(TM)", Short, et.al. (Abstract #4873) will be presented on Tuesday, April 17, 1-5pm PT.

About cHTS(TM)

To discover combinations of molecules that exhibit novel patterns of activity against disease networks, CombinatoRx, Incorporated uses its combination High Throughput Screening (cHTS(TM)) drug discovery platform. Using this proprietary platform, the company systematically searches millions of combinations across a large portfolio of phenotypic disease models, identifying patterns of activity against both known and novel targets in a broad range of disease areas. Each combination is evaluated to quantify and visualize its activity at a range of dose ratios. Combinations with synergistic therapeutic effects against disease phenotypes are flagged automatically using a custom-designed informatics backbone, then profiled to further determine their mechanism of action and product suitability. Innovations in computational biology techniques and software design automate the CombinatoRx process, enabling the company to search large numbers of combinations and rapidly select candidates with desirable patterns of activity.

About CombinatoRx

CombinatoRx, Incorporated (CRXX) is pioneering the new field of synergistic combination pharmaceuticals and has a broad product portfolio in phase 2 clinical development. Going bey
'"/>




Page: 1 2 3

Related medicine technology :

1. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
2. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
3. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
4. CombinatoRx Provides Topline Results from Phase 2 RA Study with CRx-139 and Very Low Dose Prednisolone
5. The Past, Present and Future of HLA Typing
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
10. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
(Date:5/16/2008)...resentations at ASCO Annual Meeting Will Further D... in Front-line Multiple Myeloma -, CAMBRIDGE, Mas...als,The Takeda Oncology Company, today announced ...heduled to be featured at the 2008 American Societ...icago, Illinois, May 30 -,June 3, 2008. The data w...
(Date:5/16/2008)...akers include industry and customer thought leader... Inc., the recognized,leader and trusted resource ...sted a constellation of prestigious academic medic...tners at its annual user group meeting in San,Fran... to internally and,collaboratively manage thousand...
(Date:5/16/2008)... Include:, -- Results demonstrating that TYKERB a...eaningful extension of progression-free survival (...ck both the inside and,outside of the HER2 recepto...ta demonstrating activity of TYKERB alone despite ...f trastuzumab and chemotherapy, LONDON and PHILAD...
(Date:5/16/2008)....J., May 16 /- Veridex, LLC announced... Corporation of America Holdings,(LabCorp), has co...r,prostate cancer. The new assay uses the biologic...ncer, detecting the methylation of the gene,GST-Pi... primarily in,cancer. Veridex is developing the me...
Breaking Medicine Technology:New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 2New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 3New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 4New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 5New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 6New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 7New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 8Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 2Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7Hormone Replacement May Cut Risk for Age Linked Eye Disease 16759 1Hormone Replacement May Cut Risk for Age Linked Eye Disease 16759 2Study details cost effectiveness of rheumatoid arthritis treatments for Medicare recipients 16754 1Study details cost effectiveness of rheumatoid arthritis treatments for Medicare recipients 16754 2Study details cost effectiveness of rheumatoid arthritis treatments for Medicare recipients 16754 3Consumer Watchdog Gives HMO Regulator 10 Days to Order Reinstatement of Patients Whose Policies Have Been Illegally Cancelled 16750 1Consumer Watchdog Gives HMO Regulator 10 Days to Order Reinstatement of Patients Whose Policies Have Been Illegally Cancelled 16750 2Clues to ancestral origin of placenta emerge in Stanford study 2886 1Clues to ancestral origin of placenta emerge in Stanford study 2886 2Clues to ancestral origin of placenta emerge in Stanford study 2886 3
(Date:5/16/2008)... Declaring that Primary care medicine is in a pre...nt of the American College of Physicians (ACP), to...ers and consumers to issue a call for comprehensiv...nternists and other primary care physicians. , ...care medicine in the U.S., Dr. Dale and other pane...
(Date:5/16/2008)... Fundraiser Seeks to Raise $38 Million for Life-th...ire-USNewswire/ -- Walkers in nearly,every state w...- May 17 and,18 -- by participating in GREAT STRID...c Fibrosis Foundation announced today., May is Na...rosis is a,life-threatening genetic disease that c...
(Date:5/16/2008)...untry needs is more unemployed politicians - and e...stCall/ -- Although nearly all,voters place health...list,a looming federal budgetary crunch means non...current presidential candidates is likely to becom...ty Leader Bill Frist., Jousting with Princeton Un...
(Date:5/16/2008)..., May 16 /PRNewswire-USNewswire/ -- As tropical st...rrawaddy delta, survivors of,Cyclone Nargis are vu...ny,survivors still need assistance, as exposure to... increasingly dire situation., "The people living...cover from this disaster and get back on their fee...
Breaking Medicine News(10 mins):Health News:ACP says major system reforms needed to improve the state of primary care medicine in the US 2Health News:GREAT STRIDES Walks for Cystic Fibrosis Slated for 47 States This Weekend 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 3Health News:Myanmar Cyclone Survivors Face New Challenges 2
...k of developing motor neurone disease can be reduc... high in polyunsaturated fat// or vitamin E, accor... fat included both omega-6 fat found abundantly in...n oil and omega 3 fat found in fish and nuts, repo...
...an attempt to assess and ensure health of children...tests to monitor children's growth//, motor develo...by the World Health Organization. It is hoped tha...lth care workers to take appropriate measures to e...
...attendant of a patient in an emergency ward of the... junior resident on duty//, alleging that the doct...his fiancé’s check-up. This allegation has been to.... Immediately a strike ensued by the Doctors at G...
... obese may just have a succor to turn to for help ...dy, injections of the gut hormone oxyntomodulin ma...identally, Oxyntomodulin is generated by the body,... feelings of satiation, or Feeling Full. Steve Bl...
Other Medicine News:Health News:Polyunsaturated Fat, Vitamin E Lowers Risk Of Motor Neurone Disease 2Health News:Childhood Obesity Vs Malnutrition- A Spotlight On WHO Obesity Measurement For Kids 2Health News:Childhood Obesity Vs Malnutrition- A Spotlight On WHO Obesity Measurement For Kids 3Health News:Hormone - A Shot in the Arm for Weight Loss 2
...ected curve trial lenses are ground with the same ...nd are invaluable in treating low vision patients....rs contain a disproportionately large number of le... to produce, and fewer lenses in the higher power ...
simplified focusing guidance system has made the LM-770 the easiest instrument to use of its type. Technicians can be trained to operate the LM-770 with a minimum of instruction. The instrument tells
...on electronic refractor to its line of Vision Diag...ce of a wireless, infrared remote control and is p...s. The Evolution gives the practitioner complete c...eld remote control. With the Evolution, the practi...
Marco Radiusgauges are available with either a standard or digital display as well as in either monocular or binocular form. All offer the functions of two instruments in one, measuring both the curv
Medicine Products: